Guy Ben-Betzalel
- MD
Department:
- Ella Lemelbaum Institute for Immuno-Oncology
Specialties:
- Melanoma
Languages:
- Hebrew
- English
About
Dr. Guy Ben Betzalel is the Service Director at Sheba’s Melanoma and Skin Cancer Clinic, and also heads the medical center’s Tumor-Infiltrating Lymphocytes (TIL) Program.
Earning his MD from Debrecen University in Hungary, Dr. Ben Betzalel completed his oncology residency at Sheba Medical Center and has since
dedicated his career to the research and treatment of melanoma.
Positions
- The Service Director at Sheba’s Melanoma and Skin Cancer Clinic
- Head of the Melanoma Long-Term Follow-Up Clinic at Sheba’s Ella Institute for Immuno-Oncology
- Member, Israeli Society for Clinical Oncology and Radiotherapy
- Member, American Society of Clinical Oncology
- Member, Israeli Society for Immuno-Oncology
- Member, Israeli Society for Melanoma and Skin Cancer
Education and Training
- M.D., Debrecen University, Debrecen, Hungary
- Residency in Medical Oncology, Sheba Medical Center, Israel
Board Certifications
- Medical Oncology
Publications
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Science. 2021 Feb 5;371(6529):602-609. doi: 10.1126/science.abb5920. Epub 2020 Dec 10. PMID: 33303685 Clinical Trial.
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4. PMID: 31800340
Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients.
Grynberg S, Stoff R, Asher N, Shapira-Frommer R, Schachter J, Haisraely O, Lawrence Y, Ben-Betzalel G. Ther Adv Med Oncol. 2022 Oct 31;14:17588359221131521. doi: 10.1177/17588359221131521. eCollection 2022. PMID: 36339927
Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients.
Stoff R, Grynberg S, Asher N, Laks S, Steinberg Y, Schachter J, Shapira-Frommer R, Ben-Betzalel G. Front Oncol. 2022 Nov 7;12:1020058. doi: 10.3389/fonc.2022.1020058. eCollection 2022. PMID: 36419899
The increasing role of abdominal metastesectomy for malignant melanoma in the era of modern therapeutics.
Mor E, Laks S, Assaf D, Asher N, Ben-Betzalel G, Grynberg S, Stoff R, Adileh M, Steinberg-Silman Y, Shapira-Frommer R, Schachter J, Nissan A, Zippel D. Surg Oncol. 2022 Sep;44:101808. doi: 10.1016/j.suronc.2022.101808. Epub 2022 Jul 9. PMID: 35932622
Juvenile hormone functions as a metabolic rate accelerator in bumble bees (Bombus terrestris).
Shpigler HY, Magory Cohen T, Ben-Shimol E, Ben-Betzalel R, Levin E. Horm Behav. 2021 Nov;136:105073. doi: 10.1016/j.yhbeh.2021.105073. Epub 2021 Oct 9. PMID: 34634696
MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2.
Markovits E, Harush O, Baruch EN, Shulman ED, Debby A, Itzhaki O, Anafi L, Danilevsky A, Shomron N, Ben-Betzalel G, Asher N, Shapira-Frommer R, Schachter J, Barshack I, Geiger T, Elkon R, Besser MJ, Markel G. Cancer Immunol Res. 2023 Apr 19:CIR-22-0184. doi: 10.1158/2326-6066.CIR-22-0184. Online ahead of print. PMID: 37074069
Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
Ben-Betzalel G, Steinberg-Silman Y, Stoff R, Asher N, Shapira-Frommer R, Schachter J, Markel G. Eur J Cancer. 2019 Feb;108:61-68. doi: 10.1016/j.ejca.2018.12.012. Epub 2019 Jan 14. PMID: 30648631
Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience.
Asher N, Israeli-Weller N, Shapira-Frommer R, Ben-Betzalel G, Schachter J, Meirson T, Markel G. Cancers (Basel). 2021 Jun 20;13(12):3074. doi: 10.3390/cancers13123074. PMID: 34203061
Perioperative BRAF inhibitors in locally advanced stage III melanoma.
Zippel D, Markel G, Shapira-Frommer R, Ben-Betzalel G, Goitein D, Ben-Ami E, Nissan A, Schachter J, Schneebaum S. J Surg Oncol. 2017 Dec;116(7):856-861. doi: 10.1002/jso.24744. Epub 2017 Jun 26. PMID: 28650570 Clinical Trial.
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.
Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN, Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni D, Markel G, Leibowitz-Amit R. Cancer Immunol Immunother. 2019 Sep;68(9):1493-1500. doi: 10.1007/s00262-019-02382-0. Epub 2019 Sep 9. PMID: 31501955
Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N, Marom EM, Ben-Betzalel G, Baruch EN, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G. Oncologist. 2019 May;24(5):640-647. doi: 10.1634/theoncologist.2018-0352. Epub 2019 Feb 18. PMID: 30777894
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Nissani A, Lev-Ari S, Meirson T, Jacoby E, Asher N, Ben-Betzalel G, Itzhaki O, Shapira-Frommer R, Schachter J, Markel G, Besser MJ. J Immunother Cancer. 2021 May;9(5):e001743. doi: 10.1136/jitc-2020-001743. PMID: 33990415
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma.
Asher N, Ben-Betzalel G, Lev-Ari S, Shapira-Frommer R, Steinberg-Silman Y, Gochman N, Schachter J, Meirson T, Markel G. Cancers (Basel). 2020 Aug 18;12(8):2329. doi: 10.3390/cancers12082329. PMID: 32824780
Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study.
Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, Markel G. Cancer Immunol Res. 2018 Dec;6(12):1453-1458. doi: 10.1158/2326-6066.CIR-17-0659. Epub 2018 Oct 1. PMID: 30275274
Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma.
Stoff R, Asher N, Laks S, Steinberg Y, Schachter J, Shapira-Frommer R, Grynberg S, Ben-Betzalel G. Front Oncol. 2023 May 18;13:1180988. doi: 10.3389/fonc.2023.1180988. eCollection 2023. PMID: 37274272
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G. Eur J Cancer. 2018 Sep;101:229-235. doi: 10.1016/j.ejca.2018.06.030. Epub 2018 Aug 7. PMID: 30096703
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
Besser MJ, Itzhaki O, Ben-Betzalel G, Zippel DB, Zikich D, Kubi A, Brezinger K, Nissani A, Levi M, Zeltzer LA, Ben-Nun A, Asher N, Shimoni A, Nagler A, Markel G, Shapira-Frommer R, Schachter J. Mol Carcinog. 2020 Jul;59(7):736-744. doi: 10.1002/mc.23193. Epub 2020 Apr 6. PMID: 32250515
Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy.
Bar-Hai N, Ben-Betzalel G, Stoff R, Grynberg S, Schachter J, Shapira-Frommer R, Asher N. Cancers (Basel). 2023 Jun 3;15(11):3041. doi: 10.3390/cancers15113041. PMID: 37297003
PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy.
Mor E, Schtrechman G, Nizri E, Shimonovitz M, Asher N, Ben-Betzalel G, Grynberg S, Stoff R, Miodovnik M, Adileh M, Ben-Yaacov A, Steinberg Y, Shapira R, Schachter J, Lahat G, Nissan A, Zippel D, Laks S. Eur J Surg Oncol. 2023 Jun 7:S0748-7983(23)00539-5. doi: 10.1016/j.ejso.2023.06.002. Online ahead of print. PMID: 37301639
Request a consultation
Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.
We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.
Request a consultation and a Sheba Case Manager will contact you shortly: